All Articles

The authors present their report on decreasing the time between the physician’s order for LDCT and date of actual screening.

AONN+ recognizes that for oncology navigators to excel in this competitive environment they must be empowered with the education and skill sets that are necessary to fulfill the responsibilities of their position. Certification is the answer to this need.

The authors present reports on the important role of nurse navigations in care coordination and operations management to assist navigators in preparing for the coming certification test.

In preparation for the upcoming certification test, information is provided on the essential function of nurse navigations in care coordination to assist navigators.

The following are a selection of key clinical trials that are currently recruiting patients for inclusion in investigations of new therapies or new combinations of available therapies for patients with kidney cancer, including renal cell carcinoma. Each trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their eligible patients to one of these clinical trials.

Response is a poor outcome measure of immunotherapy, according to Tanguy Seiwert, MD, who addressed this and other concerning issues in immunotherapy at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

CancerLinQ is a powerful database containing vast amounts of usable, searchable, real-world cancer information, created by oncologists, for oncologists, to improve the quality of patient care.

The revised guideline (Version 2.2016) for the management of advanced melanoma, released by the National Comprehensive Cancer Network (NCCN), shows increasing appreciation for the use of immune checkpoint inhibitors and targeted agents, as more data establish these drug classes as having superior efficacy to traditional chemotherapy.

The population of patients with multiple myeloma (MM) who are eligible for therapy has been expanded to asymptomatic patients with certain features under the most recent National Comprehensive Cancer Network (NCCN) guideline (Version 3.2016).

The chances for further policy in healthcare during an election year are minimal, said panelists during a roundtable discussion at the National Comprehensive Cancer Network 21st Annual Conference. The exception may be the Medicare Part B demonstration project for provider reimbursement for infused and injected drugs.